Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
about
A Nicotine Challenge to the Self-Medication Hypothesis in a Neurodevelopmental Animal Model of SchizophreniaDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTPET Imaging of the Human Nicotinic Cholinergic Pathway in AtherosclerosisRivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsThe human frontal lobes and frontal network systems: an evolutionary, clinical, and treatment perspectiveCurrent and future uses of neuroimaging for cognitively impaired patients.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Advances in functional neuroimaging in dementias and potential pitfallsProlonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Functional imaging of cognitive impairment in Parkinson's disease.The role of positron emission tomography imaging in understanding Alzheimer's disease.Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitroCholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.
P2860
Q24634186-B86D2BD2-6883-4C50-8DB9-8A1CF609C567Q26749755-7CE96159-E13B-4B08-8333-104B10B4E46AQ26800058-6BBC7422-C085-4B65-BE7D-0B979D260E5DQ28479242-04184BEC-5A1D-452E-9F6F-B266C21FA843Q28709470-3D220916-2A60-4E8D-8A38-485B21F350D8Q31143267-2812DFB2-50C9-43C6-A85C-612097CDB120Q35840623-D1CCD5D5-87B0-4768-8D94-5A968F04D8A8Q35952260-726EAA00-40B4-457D-9BAE-FFE801E57084Q36842150-B3328E8A-2A92-4C32-B3B6-7538DBD16CA8Q37070395-CE20CE8A-A43F-4050-8691-68CA51906018Q37781045-2DDFEDE8-4C4B-4D9E-B918-F9E6D9A2AC1CQ38370609-3A87AF92-843D-44E1-92CA-52317C1E9160Q39388222-FA1FB420-9537-4F24-B4F2-278DED752CBEQ42728333-5346B562-9616-4899-B451-6DF4267E74FBQ43613870-D8BE3050-62D5-4247-8CC7-C0FE83CF7FE6Q48009480-89BAC5A2-E04E-44A1-BDA5-10437D950A9E
P2860
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@en
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@nl
type
label
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@en
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@nl
prefLabel
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@en
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@nl
P2860
P50
P1433
P1476
Changes in brain 11C-nicotine ...... treatment as assessed by PET.
@en
P2093
Ahmadul Kadir
Anders Wall
P2860
P2888
P304
P356
10.1007/S00213-007-0725-Z
P577
2007-02-20T00:00:00Z